Study finds convalescent plasma therapy ineffective for COVID-19

In February, the National Institutes of Health terminated an ambitious clinical trial to study the effectiveness of COVID-19 convalescent plasma in treating patients with mild to moderate disease. The therapy, the NIH determined, showed little benefit in an interim analysis. In a new paper published on Aug. 18 in The New England Journal of Medicine, researchers from Stanford Medicine and a dozen other health care organizations detail how a treatment once considered promising did not prove effective.